Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo

European Journal of Pharmacology

Volumn 360, Issue 2-3, 1998, Pages 155-163

  Ferger, Boris ^a   Spratt, Christopher ^a   Teismann, Peter ^a   Seitz, Gunther ^a   Kuschinsky, Klaus ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cytisine; Hydroxyl radical; Iron chelator; MPTP (1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine); Parkinson's disease; S PBN

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTISINE; DOPAMINE; HYDROXYL RADICAL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; MALE; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALKALOIDS; ANIMALS; AZOCINES; BENZENESULFONATES; DOPAMINE; DOPAMINE AGENTS; HYDROXYL RADICAL; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; QUINOLIZINES;

EID: 0032491573     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00696-7     Document Type: Article

References (29)

1. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferroxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1441-1444.
2. Ben-Shachar D., Youdim M.B.H. Intranigral iron injection induces behavioral and biochemical 'parkinsonism' in rats. J. Neurochem. 57:1991;2133-2135.
3. Cohen G., Farooqui R., Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. USA. 94:1997;4890-4894.
4. Coyle J.T., Puttfarken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
5. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
6. Dexter D.T., Carayon A., Vidaihet M., Ruberg M., Agid F., Agid Y., Lees A.J., Wells F.R., Jenner P., Marsden C.D. Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55:1990;16-20.
7. Di Monte D.A., Schipper H.M., Hetts S., Langston J.W. Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures. Glia. 15:1995;203-206.
8. Ehringer H., Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klinische Wochenschrift. 38:1960;1236-1239.
9. Faucheux B.A., Nillesse N., Damier P., Spick G., Mouatt-Prigent A., Pierce A., Leveugle B., Kubis N., Hauw J.J., Agid Y. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA. 92:1995;9603-9607.
10. Ferger B., van Amsterdam C., Seyfried C., Kuschinsky K. Effects of α-phenyl-tert-butylnitrone and selegiline on hydroxyl free radicals in rat striatum produced by local application of glutamate. J. Neurochem. 70:1998;276-280.
11. Floyd R.A., Watson J.J., Wong P.K. Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate products. J. Biochem. Biophys. Methods. 10:1984;221-235.
12. Gassen M., Youdim M.B. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol. Toxicol. 80:1997;159-166.
13. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B.H. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
14. Lan J., Jiang D.H. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural. Transm. 104:1997;649-660.
15. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
16. Lefkowitz, R.J., Hoffman, B.B., Taylor, P., 1996. Neurotransmission: The autonomic and somatic motor nervous system, In: Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill Health Profession Division, New York, pp. 105-139.
17. Logroscino G., Marder K., Graziano J., Freyer G., Slavkovich V., LoIacono N., Cote L., Mayeux R. Altered systemic iron metabolism in Parkinson's disease. Neurology. 49:1997;714-717.
18. Mochizuki H., Imai H., Endo K., Yokomizo K., Murata Y., Hattori N., Mizuno Y. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168:1994;251-253.
19. Monteiro H.P., Winterbourn C.C. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38:1989;4177-4182.
20. Oestreicher E., Sengstock G.J., Riederer P., Olanow C.W., Dunn A.J., Arendash G.W. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660:1994;8-18.
21. Olanow, C.W., Youdim, M.B.H., 1996. Iron and neurodegeneration: prospects for neuroprotection. In: Olanow, C.W., Jenner, P., Youdim, M. (Eds.), Neurodegeneration and Neuroprotection in Parkinson's Disease. Academic Press, London, pp. 55-67.
22. Reavill C., Walther B., Stolerman I.P., Testa B. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology. 29:1990;619-624.
23. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
24. + toxicity on striatal dopaminergic terminals. J. Neurochem. 68:1997;732-738.
25. Sengstock G.J., Olanow C.W., Menzies R.A., Dunn A.J., Arendash G.W. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35:1993;67-82.
26. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M.B.H. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56:1991;978-982.
27. Temlett J.A., Landsberg J.P., Watt F., Grime G.W. Increased iron in the substantia nigra compacta of MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental analysis. J. Neurochem. 62:1994;134-146.
28. Wesemann W., Blaschke S., Solbach M., Grote C., Clement H.-W., Riederer P. Intranigral injected iron progressively reduces striatal dopamine metabolism. J. Neural Transm. (PD Sect.). 8:1994;209-214.
29. Youdim M.B., Ben-Shachar D., Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8:1993;1-12.